Blueprint Medicines (BPMC) Reports Q3 Loss of $1.93/Share

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.93), versus $1.66 reported last year. Revenue for the quarter came in at $9.14 million, versus $1.1 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• nVent Electric (NVT) PT Raised to $220; Bernstein SocGen: 'Our top pick going into earnings'
• Bernstein: 'Case studies from Microchip and other Semiconductor LTAs - What's different this time?'